OnKure Therapeutics (OKUR) Stock: Why It's Down Today
Updated Oct 19, 2026, 12:05 PM ET · intraday price
- Trading at $2.07 as of 12:05 PM ET, -1.67% vs the prior close of $2.10.
- Volume 95.96K shares, 0.4x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
OKUR dips 1.7% to $2.07, a 52-week low, 5 down days in a row. Trading at $2.07 (intraday, 12:05 PM ET), -1.67% vs the prior close of $2.10. Day range $2.02–$2.17, opened at $2.17.
OKUR daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — OKUR dips 1.7% to $2.07, a 52-week low, 5 down days in a row
- Trading at $2.07 (intraday, 12:05 PM ET), -1.67% vs the prior close of $2.10. Day range $2.02–$2.17, opened at $2.17.
- Volume was 95.96K shares, 0.4x its 50-day average of 268.24K — lighter than usual.
- Price is -34.9% vs its 50-day average ($3.17) and -43.1% vs its 200-day average ($3.63).
- 52-week range $2.01–$5.38; the current price sits at 2% of that range, 61.6% below the 52-week high.
- That makes 5 straight losses.
Oct 16, 2026 — OKUR dips 1.4% to $2.10, a 52-week low, 4 down days in a row
- Closed at $2.10, -1.41% vs the prior close of $2.13. Day range $2.01–$2.14, opened at $2.14.
- Volume was 378.59K shares, 1.4x its 50-day average of 262.24K.
- Price is -34.7% vs its 50-day average ($3.22) and -42.2% vs its 200-day average ($3.64).
- 52-week range $2.01–$5.38; today's close sits at 3% of that range, 61.0% below the 52-week high.
- That makes 4 straight losses.
Oct 15, 2026 — OKUR slides 5.3% to $2.13, a 52-week low, 3 down days in a row
- Closed at $2.13, -5.33% vs the prior close of $2.25. Day range $2.09–$2.28, opened at $2.26.
- Volume was 349.90K shares, 1.3x its 50-day average of 260.25K.
- Price is -34.6% vs its 50-day average ($3.26) and -41.5% vs its 200-day average ($3.64).
- 52-week range $2.09–$5.38; today's close sits at 1% of that range, 60.4% below the 52-week high.
- That makes 3 straight losses.
Oct 14, 2026 — OKUR slides 4.1% to $2.25, a 52-week low
- Closed at $2.25, -4.05% vs the prior close of $2.35. Day range $2.21–$2.38, opened at $2.29.
- Volume was 381.20K shares, 1.5x its 50-day average of 256.66K.
- Price is -31.8% vs its 50-day average ($3.30) and -38.2% vs its 200-day average ($3.64).
- 52-week range $2.13–$5.38; today's close sits at 4% of that range, 58.2% below the 52-week high.
Oct 13, 2026 — OKUR slides 3.1% to $2.35
- Closed at $2.35, -3.10% vs the prior close of $2.42. Day range $2.31–$2.40, opened at $2.40.
- Volume was 232.60K shares, 0.9x its 50-day average of 255.21K.
- Price is -29.7% vs its 50-day average ($3.33) and -35.7% vs its 200-day average ($3.65).
- 52-week range $2.13–$5.38; today's close sits at 7% of that range, 56.4% below the 52-week high.
Oct 12, 2026 — OKUR rises 0.4% to $2.42
- Closed at $2.42, +0.41% vs the prior close of $2.41. Day range $2.40–$2.47, opened at $2.41.
- Volume was 146.40K shares, 0.6x its 50-day average of 257.07K — lighter than usual.
- Price is -28.1% vs its 50-day average ($3.37) and -33.7% vs its 200-day average ($3.65).
- 52-week range $2.13–$5.38; today's close sits at 9% of that range, 55.0% below the 52-week high.
Oct 9, 2026 — OKUR jumps 4.8% to $2.41 on 2.5x normal volume
- Closed at $2.41, +4.78% vs the prior close of $2.30. Day range $2.23–$2.42, opened at $2.29.
- Volume was 609.20K shares, 2.5x its 50-day average of 246.14K — unusually heavy trading.
- Price is -29.0% vs its 50-day average ($3.40) and -34.0% vs its 200-day average ($3.65).
- 52-week range $2.13–$5.38; today's close sits at 9% of that range, 55.2% below the 52-week high.
Oct 8, 2026 — OKUR dips 2.1% to $2.30, a 52-week low on 2.2x normal volume
- Closed at $2.30, -2.13% vs the prior close of $2.35. Day range $2.13–$2.46, opened at $2.34.
- Volume was 519.60K shares, 2.2x its 50-day average of 237.40K — unusually heavy trading.
- Price is -32.9% vs its 50-day average ($3.43) and -37.0% vs its 200-day average ($3.65).
- 52-week range $2.13–$5.38; today's close sits at 5% of that range, 57.2% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — OKUR slides 4.5% to $2.35, a 6-month low
- Closed at $2.35, -4.47% vs the prior close of $2.46. Day range $2.30–$2.46, opened at $2.41.
- Volume was 260.70K shares, 1.1x its 50-day average of 234.11K.
- Price is -32.1% vs its 50-day average ($3.46) and -35.7% vs its 200-day average ($3.66).
- 52-week range $2.23–$5.38; today's close sits at 4% of that range, 56.3% below the 52-week high.
Oct 6, 2026 — OKUR slides 6.5% to $2.46, a 6-month low
- Closed at $2.46, -6.46% vs the prior close of $2.63. Day range $2.41–$2.65, opened at $2.65.
- Volume was 327.50K shares, 1.4x its 50-day average of 229.22K.
- Price is -29.6% vs its 50-day average ($3.49) and -32.8% vs its 200-day average ($3.66).
- 52-week range $2.23–$5.38; today's close sits at 7% of that range, 54.3% below the 52-week high.
Oct 5, 2026 — OKUR rises 2.7% to $2.63 on 2.8x normal volume
- Closed at $2.63, +2.73% vs the prior close of $2.56. Day range $2.42–$2.67, opened at $2.56.
- Volume was 626.20K shares, 2.8x its 50-day average of 220.41K — unusually heavy trading.
- Price is -25.4% vs its 50-day average ($3.52) and -28.2% vs its 200-day average ($3.66).
- 52-week range $2.23–$5.38; today's close sits at 13% of that range, 51.1% below the 52-week high.
Oct 2, 2026 — OKUR rises 0.8% to $2.56 on 2.5x normal volume
- Closed at $2.56, +0.79% vs the prior close of $2.54. Day range $2.46–$2.61, opened at $2.57.
- Volume was 526.90K shares, 2.5x its 50-day average of 210.95K — unusually heavy trading.
- Price is -28.0% vs its 50-day average ($3.55) and -30.1% vs its 200-day average ($3.66).
- 52-week range $2.23–$5.38; today's close sits at 10% of that range, 52.4% below the 52-week high.
OKUR bull case vs bear case (from the data)
- No clear positive signal in the price trend, filings or insider data right now.
- Price is -34.9% vs its 50-day average — short-term trend is down.
- Price is -43.1% vs its 200-day average — below the long-term trend line.
- Latest fiscal-year net income: loss of $59.52M.
- Insider selling outweighs buying: 25 sales vs 0 open-market buys among the 25 most recent reported insider trades (Form 4, last 12 months).
- Share count up 21.1% in a year (dilution).
- High volatility: average daily move of 3.4% over 20 sessions.
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
OKUR latest news & SEC filings
Every SEC filing by or about OKUR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Saccomano Nicholas A sold 87 shares at $2.97 (≈$259) on Sep 21, 2026; now holds 11,160
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Leverone Jason A. sold 302 shares at $2.97 (≈$898) on Sep 21, 2026; now holds 18,500
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 10, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 4, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$15.35M (prior year -$15.39M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.31 (prior year -$1.14) (loss narrowed vs Jun 30, 2025)
Things to know before you trade OKUR
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Mar 12, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.37% (largest 6.8%). That is a volatile stock.
- Liquidity: about 437.47K shares (≈$903.37K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.07 vs a range of $2.01–$5.38 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Jason A. Leverone sold 302 shares on Sep 21, 2026.
- Latest filings: 8-K Aug 13, 2026; 8-K Aug 4, 2026; 10-Q Aug 4, 2026.
- Share count: 40.50M shares outstanding (Aug 3, 2026), +21.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
OKUR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 2.17 | 2.17 | 2.02 | 2.07 | 95.96K |
| Oct 16, 2026 | 2.14 | 2.14 | 2.01 | 2.10 | 386.00K |
| Oct 15, 2026 | 2.26 | 2.28 | 2.09 | 2.13 | 349.90K |
| Oct 14, 2026 | 2.29 | 2.38 | 2.21 | 2.25 | 381.20K |
| Oct 13, 2026 | 2.40 | 2.40 | 2.31 | 2.35 | 232.60K |
| Oct 12, 2026 | 2.41 | 2.47 | 2.40 | 2.42 | 146.40K |
| Oct 9, 2026 | 2.29 | 2.42 | 2.23 | 2.41 | 609.20K |
| Oct 8, 2026 | 2.34 | 2.46 | 2.13 | 2.30 | 519.60K |
| Oct 7, 2026 | 2.41 | 2.46 | 2.30 | 2.35 | 260.70K |
| Oct 6, 2026 | 2.65 | 2.65 | 2.41 | 2.46 | 327.50K |
| Oct 5, 2026 | 2.56 | 2.67 | 2.42 | 2.63 | 626.20K |
| Oct 2, 2026 | 2.57 | 2.61 | 2.46 | 2.56 | 526.90K |
| Oct 1, 2026 | 2.72 | 2.83 | 2.50 | 2.54 | 2.08M |
| Sep 30, 2026 | 2.63 | 2.79 | 2.50 | 2.72 | 831.40K |
| Sep 29, 2026 | 2.78 | 2.80 | 2.47 | 2.60 | 339.80K |
| Sep 28, 2026 | 2.87 | 2.88 | 2.60 | 2.76 | 442.20K |
| Sep 25, 2026 | 2.93 | 3.00 | 2.86 | 2.90 | 91.40K |
| Sep 24, 2026 | 2.96 | 3.05 | 2.88 | 2.93 | 149.70K |
| Sep 23, 2026 | 3.09 | 3.24 | 2.90 | 2.94 | 149.70K |
| Sep 22, 2026 | 3.06 | 3.11 | 2.91 | 3.10 | 200.80K |
About OnKure Therapeutics
OnKure Therapeutics (OKUR) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOULDER, CO. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1637715.
OKUR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| R Michael Carruthers | Director | Aug 11, 2026 |
| Michael G Grey | Director | Aug 11, 2026 |
| Valerie Malyvanh Jansen | Director | Aug 11, 2026 |
| Isaac Manke | Director | Aug 13, 2026 |
| Edward T Mathers | Director | Aug 11, 2026 |
| Andrew John Phillips | Director | Aug 11, 2026 |
| Liam Ratcliffe | Director | Aug 11, 2026 |
| Nicholas A Saccomano | President and CEO | Sep 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Samuel Agresta | Chief Medical Officer | Aug 11, 2026 |
| Dylan Hartley | Chief Scientific Officer | Aug 11, 2026 |
| Jason A. Leverone | Chief Financial Officer | Sep 23, 2026 |
| Nicholas A Saccomano | President and CEO | Sep 23, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 21, 2026 | Jason A. Leverone | Sale | 302 | $2.97 |
| Sep 21, 2026 | Jason A. Leverone | Sale | 302 | $2.97 |
| Sep 21, 2026 | Jason A. Leverone | Sale | 302 | $2.97 |
| Sep 21, 2026 | Jason A. Leverone | Sale | 302 | $2.97 |
| Sep 21, 2026 | Nicholas A Saccomano | Sale | 87 | $2.97 |
| Sep 21, 2026 | Nicholas A Saccomano | Sale | 87 | $2.97 |
| Sep 21, 2026 | Nicholas A Saccomano | Sale | 87 | $2.97 |
| Sep 21, 2026 | Nicholas A Saccomano | Sale | 87 | $2.97 |
| Jun 22, 2026 | Jason A. Leverone | Sale | 303 | $4.40 |
| Jun 22, 2026 | Jason A. Leverone | Sale | 303 | $4.40 |
| Jun 22, 2026 | Jason A. Leverone | Sale | 303 | $4.40 |
| Jun 22, 2026 | Jason A. Leverone | Sale | 303 | $4.40 |
| Jun 22, 2026 | Nicholas A Saccomano | Sale | 86 | $4.40 |
| Jun 22, 2026 | Nicholas A Saccomano | Sale | 86 | $4.40 |
| Jun 22, 2026 | Nicholas A Saccomano | Sale | 86 | $4.40 |
OKUR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-59.52M | -4.40 | $-51.83M |
| Dec 31, 2024 | $0 | $-52.67M | -15.28 | $-51.12M |
| Dec 31, 2023 | — | $-35.31M | -124.41 | $-34.55M |
| Dec 31, 2022 | — | $-51.95M | -2.12 | $-47.36M |
| Dec 31, 2021 | — | $-39.77M | -2.19 | $-37.98M |
Latest balance sheet: total assets $179.35M, total liabilities $7.25M, cash $166.50M (as of Jun 30, 2026).
OKUR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $4.10 |
| May 5, 2026 | 8-K Item 2.02 (results) | $4.52 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $3.52 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $3.16 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $2.00 |
| May 6, 2025 | 8-K Item 2.02 (results) | $2.23 |
| Mar 10, 2025 | 8-K Item 2.02 (results) | $4.96 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Mar 28, 2024 | 8-K Item 2.02 (results) | — |
| Nov 13, 2023 | 8-K Item 2.02 (results) | — |
| Aug 10, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on OKUR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: intraday data as of Oct 19, 2026, 12:05 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.